Valion Bio to Release Q1 2026 Results, Spotlighting Entolimod & Entolasta
Valion Bio Inc. releases Q1 2026 results on May 14, showcasing progress on Entolimod® for radiation syndrome, Entolasta® for oncology, and cost‑saving Velocity Bioworks partnership.
2 minutes to read